AVIR News and Press, Atea Pharmaceuticals Inc. From 05/08/23

2023-05-08 20:51:06 ET Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Results Conference Call May 08, 2023 04:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder and Chief E...

2023-05-08 16:13:26 ET Atea Pharmaceuticals press release ( NASDAQ: AVIR ): Q1 GAAP EPS of -$0.43 beats by $0.07 . Cash, Cash Equivalents and Marketable Securities: $620.5 million at March 31, 2023 compared to $646.7 million at December 31, 2022. For further deta...

Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV on track for first patient dosed 2...

BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live confer...

2023-04-25 09:00:39 ET The U.S. Food and Drug Administration (FDA) granted fast track designation to Atea Pharmaceuticals' ( NASDAQ: AVIR ) bemnifosbuvir to treat COVID-19. The oral antiviral drug is being evaluated in a phase 3 trial called SUNRISE-3 to treat COVID-19 in...

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the United States Food a...

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for serious viral diseases, today announced the presentation of the f...

Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies Bemnifosbuvir retains activity against all SARS -CoV-2 variants of concern evaluated as well as other human coronaviruses such as HCoV-229E, HCoV-OC43, and SA...

BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for several viral diseases, today announced six upcoming presentation...

Atea Pharmaceuticals, Inc. (AVIR) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM Company Participants Jonae Barnes - Senior VP, Investor Relations & Corporate Communications Jean Sommadossi - Founder, Chairman & CEO Andrea Corcoran - CFO & Execu...